PORTON

Enabling the Public’ s Early Access to Good Medicines

NEWSLETTER

April 2025

Porton Pharma Solutions Ltd.

Contents

Technical Enabling

Challenges and Advances in CMC Process Development of BsADCs

April 23, 2025

Antibody drug conjugates (ADCs) have seen significant breakthroughs and reached numerous milestones since 2000 when the first ADC was approved by the FDA and have shown great promise for the treatment of cancer. First generation ADCs were designed to use the affinity of an antibody towards a specific cellular target to bring the cytotoxic payload to the tumor, for example.

However, some level of off-target toxicity was often seen with many ADCs because other cellular interactions could occur prior to the payload physically reaching its intended target or the payload could cleave off. These events could lead to unintended death of non-cancerous cells.



Read more

Comprehensive Analytical R&D and QC Expertise in Pharmaceutical Development

April 27, 2025

This white paper details **Porton**'s extensive capabilities in Analytical R&D and Quality Control for pharmaceutical drug development. It highlights our expertise in method development, structure elucidation, and method troubling.

Our goal is to ensure the highest standards of **quality and efficiency in drug development and manufacturing**.

Read more

Services & Solutions

Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy

April 16, 2025

Porton Advanced announced its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received IND approval from China's NMPA. This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

As the exclusive CDMO partner for this program, **Porton Advanced** provided comprehensive process development and manufacturing services, including plasmid, lentiviral vectors and final CAR-T cell products. We successfully manufactured dozens of batches of clinical-grade investigational products for Investigator-Initiated Trials (IITs), with all batches passing quality control on the first attempt.

Read more

Company Events

Porton Reports 18% Sales Growth in Q1 2025

April 25, 2025

Porton Pharma Solutions Ltd. (SZSE: 300363) is pleased to share the first quarter results 2025, which have propelled us towards the fulfillment of our annual business objectives. **The Q1 2025 reported sales growth of 18% to ￥801.1 Million.** This resurgence in revenue growth is primarily attributed to the strong performance of our overseas markets.

Read more

Marketing Activities

Previous Events

Interphex

April 1-3

Javits Center, NYC

CPHI Japan 2025

April 9-11

Tokyo, Japan

Applied Pharmaceutical Chemistry 2025

April 10

Boston MA, United States

20th Annual Garnet E. Peck Symposium

April 10

West Lafayette, IN, United States

11 STILLE

April 26

Colorado State University, United States

Upcoming Events

Stay Updated on the Latest Developments, Click to Schedule Your Appointment

Events	Date	Venue	Booth
Swiss Biotech Day	May 5-6	Basel, Switzerland	/
2nd ADC Linker & Conjugation Summit	May 6-8	Boston MA, United States	/
BIO Korea 2025	May 7-9	Seoul, Korea	J30
ASGCT Annual Meeting	May 13-17	Portland, United States	1448
Boston ABI Lab Lunch and Learn	May 15	Natick MA, United States	/
The Fifth China Gene & Cell Therapy Innovation Forum (CGCT 2025)	May 16-17	Shenzhen, China	/
CPhI Americas 2025	May 20-22	Pennsylvania Convention Center, Philadelphia, United States	405
ChemSpec Europe	June 4-5	Koelnmesse, Germany	4T29
BOS Basel 2025	June 11-12	Basel, Switzerland	62
EWOC: Empowering Women in Organic Chemistry	June 12-13	Chicago, Illinois, United States	/
BIO International Convention	June 16-19	Boston MA, United States	/
The 7th Grant Symposium	June 18-20	Minneapolis MN, United States	/
The 28th ACS Annual Green Chemistry & Engineering Conference	June 23-26	Pittsburgh, PA, United States	/
CPHI China	June 24-26	Shanghai, China	E2A32

Customized Development and Manufacturing

Technical Solutions for Conventional and New Drug Modalities

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial

- Small Molecules
- Tides
- Biologics and Conjugates
- Advanced Therapy Medicinal Products

Operational Excellence	IP · QA · EHS · RA · PM · Supply Chain
Global Site Compliance	U.S. FOOD & DRUG ADMINISTRATION · World Health Organization · EUROPEAN MEDICINES AGENCY SCIENCE · MEDICINES · HEALTH · PMDA · 国家药品监督管理局 National Medical Products Administration

PORTON

A Customer Centric, Innovative, and Reliable CDMO with Global Solutions

Please contact us to help you on your next development project and achieve your business goals.

LinkedIn
Porton Pharma Solutions

business@portonpharma.com
www.portonpharma.com

Contact Us